Young J B, Windsor N T, Smart F W, Kleiman N S, Weilbaecher D G, Noon G P, Nelson D L, Lawrence E C
Multi-Organ Transplant Center, Methodist Hospital, Houston, Texas.
Transplantation. 1991 Mar;51(3):636-41. doi: 10.1097/00007890-199103000-00018.
Successful cardiac transplantation requires suppression of rejection, and endomyocardial biopsy is generally used to quantify this and guide immunotherapy. Biopsy, however, is an invasive, costly, cardiac catheterization with repetition limited. Since rejection requires lymphocyte activation, an alternative method of assessing rejection dynamics might be ELISA determination of soluble interleukin-2 receptor (sIL-2R) levels since induction of the interleukin-2 ligand and its receptor is required. Reports suggest that sIL-2R levels rise during kidney, liver, and heart-lung allograft rejection and heart recipients have an adverse prognosis if sIL-2R is elevated postoperatively. It is unclear, however, if serial measurements or single determinations are sufficient or if change from a baseline assessment is important. The purpose of this study was to determine if an isolated sIL-2R level after heart transplant predicted endomyocardial biopsy score at that moment. To do this, we prospectively followed 60 consecutive patients after orthotopic heart transplant and correlated 479 endomyocardial biopsy scores (McAllister scale 0-10) with matched sIL-2R levels. Regression analysis demonstrated minimal relationship between sIL-2R level and biopsy score (r =.11, r2 =.01, P=.009). When the maximum sIL-2R level for each individual patient was compared with the matched biopsy score, regression analysis revealed r=.04, r2=.001, P=.8. Likewise, when all biopsy scores and sIL-2R levels for each patient were meaned, analysis showed r=.14, r2=.02, P=.26. Thus in heart transplant patients, there is poor correlation between an isolated biopsy score and matched sIL-2R level. However, when mean +/- SEM sIL-2R was determined for severe rejection (score 7-10) and compared with sIL-2R for all other grades, it was significantly higher (1600 +/- 257 vs. 423 +/- 57 U/ml; P=.012). Still, the sensitivity, specificity, and predictive value of an sIL-2R level above 1000 U/ml predicting severe rejection was only 52%, 63%, and 8%. It would be difficult, therefore, to use a single sIL-2R determination after heart transplant to foretell the endomyocadial biopsy score. Serial measurements or quantification of a change in sIL-2R level from baseline might be more predictive of rejection severity.
成功的心脏移植需要抑制排斥反应,心内膜活检通常用于量化排斥反应并指导免疫治疗。然而,活检是一种侵入性、成本高的心脏导管检查,且重复次数有限。由于排斥反应需要淋巴细胞激活,评估排斥反应动态的另一种方法可能是通过酶联免疫吸附测定法(ELISA)检测可溶性白细胞介素-2受体(sIL-2R)水平,因为白细胞介素-2配体及其受体的诱导是必需的。报告表明,在肾、肝和心肺移植排斥反应期间,sIL-2R水平会升高,心脏移植受者术后若sIL-2R升高则预后不良。然而,尚不清楚连续测量或单次测定是否足够,或者与基线评估的变化是否重要。本研究的目的是确定心脏移植后单独的sIL-2R水平是否能预测当时的心内膜活检评分。为此,我们对60例原位心脏移植后的连续患者进行了前瞻性随访,并将479份心内膜活检评分(麦卡利斯特量表0 - 10分)与匹配的sIL-2R水平进行关联分析。回归分析显示sIL-2R水平与活检评分之间关系极小(r = 0.11,r² = 0.01,P = 0.009)。当将每个患者的最高sIL-2R水平与匹配的活检评分进行比较时,回归分析显示r = 0.04,r² = 0.001,P = 0.8。同样,当对每个患者的所有活检评分和sIL-2R水平进行均值计算时,分析显示r = 0.14,r² = 0.02,P = 0.26。因此,在心脏移植患者中,单独的活检评分与匹配的sIL-2R水平之间相关性较差。然而,当测定严重排斥反应(评分7 - 10分)的平均±标准误sIL-2R,并与所有其他等级的sIL-2R进行比较时,前者显著更高(1600±257 vs. 423±57 U/ml;P = 0.012)。尽管如此,sIL-2R水平高于1000 U/ml预测严重排斥反应的敏感性、特异性和预测价值仅为52%、63%和8%。因此,心脏移植后使用单次sIL-2R测定来预测心内膜活检评分会很困难。连续测量或量化sIL-2R水平相对于基线的变化可能更能预测排斥反应的严重程度。